Anti-pd-1 monoclonal antibody, and pharmaceutical composition and use thereof

The invention relates to the field of tumor treatments and molecular Immunology, and specifically, to an anti-PD-1 monoclonal antibody, and a fragment antigen-binding fragment, pharmaceutical composition and use thereof. The monoclonal antibody comprises a heavy chain variable region comprising an amino acid sequence such as CDR1-3 as indicated by a SEQ ID NO. 13-15, and a light chain variable region comprising an amino acid sequence such as CDR1-3 as indicated by a SEQ ID NO. 16-18. The monoclonal antibody can specifically bind with PD-1, remove immunosuppression of PD-1 with respect to an organism, and activate a T-lymphocyte.